Prevention is the most cost-effective tool against Lyme disease. If you never get infected, there is no disease to diagnose, treat, or manage. Yet the primary prevention tools available today — tick repellents, protective clothing, and tick checks — depend entirely on individual behavior and have real-world adherence limitations. A vaccine could change that.
The History of Lyme Vaccination
LYMErix, a Lyme disease vaccine based on the outer surface protein A (OspA) of Borrelia burgdorferi, was approved by the FDA in 1998 and shown to be approximately 76% effective in clinical trials. However, it was withdrawn from the market in 2002 — not because of proven safety concerns, but largely due to declining sales following a wave of scientifically unsupported claims about side effects. In retrospect, most experts consider the withdrawal a significant public health setback.
The Current Pipeline
Research into Lyme prevention and vaccination has accelerated significantly in recent years:
VLA15 (Lyme Disease Vaccine Candidate)
VLA15 is a multivalent OspA-based vaccine targeting six major Borrelia species responsible for Lyme disease in North America and Europe. Phase 3 trial enrollment was completed in 2023. Results are expected in 2025–2026.
mRNA-Based Tick-Targeted Vaccine
A novel approach that targets tick saliva proteins rather than Borrelia antigens — potentially protecting against multiple tick-borne diseases simultaneously. Preclinical results were promising; human trials are anticipated.
Personal Prevention in the Meantime
Until a vaccine is licensed and available, personal prevention measures remain the primary defense. See our Preventing Tick Bites guide for evidence-based strategies.